Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Noteableon May 28, 2024 11:45am
217 Views
Post# 36060430

Roche/Genentech head deal-maker moves on after 14 years

Roche/Genentech head deal-maker moves on after 14 years May 28, 2024 - James Sabry, global head at Roche Pharma Partnering, is moving on from the Swiss pharma giant. 

He will be succeeded by Boris Zatra, Roche’s head of group business development, who will take on the title of head of corporate business development on July 1. He will report to Roche CEO Thomas Schinecker. 

Zatra, presently Head of Group Business Development, will be appointed as the Head of Corporate Business Development. This new role will merge the functions of Pharma Partnering and Group Business Development, as stated in Roche’s Monday announcement. Zatra has been with Roche since 2012, starting his journey in Basel.


https://www.mmm-online.com/home/channel/people-moves/james-sabry-roche-global-head-of-partnering-retires/
<< Previous
Bullboard Posts
Next >>